Logotype for Novolog (Pharm-Up 1966) Ltd

Novolog (NVLG) Q2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Novolog (Pharm-Up 1966) Ltd

Q2 2025 earnings summary

19 Aug, 2025

Executive summary

  • H1-2025 revenue was ₪2,021.6M, up from ₪1,840.8M year-over-year, mainly due to logistics growth and increased private sector sales.

  • Net profit for H1-2025 was ₪41.4M, compared to ₪26.7M in H1-2024, reflecting improved operational performance despite one-time SAP expenses.

  • Adjusted EBITDA for H1-2025 was ₪63.4M, up from ₪41.5M in H1-2024.

  • Dividend of ₪10M (₪0.01958 per share) declared for September 2025; policy remains at 70% of net profit.

  • Maintains a strong, debt-free balance sheet and robust cash reserves.

Financial highlights

  • H1-2025 gross profit was ₪180.8M, up from ₪110.9M in H1-2024.

  • H1-2025 operating profit was ₪62.3M, compared to ₪37.7M in H1-2024.

  • Cash flow from operating activities in H1-2025 was ₪158.5M, up from ₪74.4M in H1-2024.

  • Cash and equivalents at end of H1-2025 were ₪247.6M; equity stood at ₪382.1M.

  • Total assets as of June 30, 2025, were ₪3,037.1M.

Outlook and guidance

  • Adjusted EBITDA for 2025 is projected at ₪96–102M, excluding extraordinary events.

  • Efficiency measures underway in logistics after SAP system integration challenges.

  • Focus on expanding digital health services and integrating new projects for future growth.

  • Growth strategy emphasizes operational efficiency, innovation, and customer-centricity.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more